Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor

Ronald Tilton, Takahiko Kawamura, Katherine C. Chang, Yasuo Ido, Robert J. Bjercke, Clifford C. Stephan, Tommy A. Brock, Joseph R. Williamson

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Skin chambers were mounted on the backs of Sprague-Dawley rats and 1 wk later, granulation tissue in the chamber was exposed twice daily for 7 d to 5 mM glucose, 30 mM glucose, or 1 mM sorbitol in the presence and absence of neutralizing VEGF antibodies. Albumin permeation and blood flow were increased two- to three- fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Blood flow and albumin permeation were increased ~ 2.5-fold 1 h after topical application of recombinant human VEGF and these effects were prevented by nitric oxide synthase (NOS) inhibitors (aminoguanidine and N(G)-monomethyl L-arginine). Topical application of a superoxide generating system increased albumin permeation and blood flow and these changes were markedly attenuated by VEGF antibody and NOS inhibitors. Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore. A23187, mimicked effects of glucose, sorbitol and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by 'hypoxia-like' cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway.

Original languageEnglish (US)
Pages (from-to)2192-2202
Number of pages11
JournalJournal of Clinical Investigation
Volume99
Issue number9
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Sorbitol
Vascular Endothelial Growth Factor A
Blood Vessels
Glucose
Albumins
Nitric Oxide Synthase
Superoxides
Antibodies
Granulation Tissue
Calcium Ionophores
Ionophores
Calcimycin
Nitroprusside
Sprague Dawley Rats
Arginine
Nitric Oxide
Skin

Keywords

  • albumin permeation
  • blood flow
  • nitric oxide
  • polyol pathway
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tilton, R., Kawamura, T., Chang, K. C., Ido, Y., Bjercke, R. J., Stephan, C. C., ... Williamson, J. R. (1997). Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. Journal of Clinical Investigation, 99(9), 2192-2202.

Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. / Tilton, Ronald; Kawamura, Takahiko; Chang, Katherine C.; Ido, Yasuo; Bjercke, Robert J.; Stephan, Clifford C.; Brock, Tommy A.; Williamson, Joseph R.

In: Journal of Clinical Investigation, Vol. 99, No. 9, 01.05.1997, p. 2192-2202.

Research output: Contribution to journalArticle

Tilton, R, Kawamura, T, Chang, KC, Ido, Y, Bjercke, RJ, Stephan, CC, Brock, TA & Williamson, JR 1997, 'Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor', Journal of Clinical Investigation, vol. 99, no. 9, pp. 2192-2202.
Tilton R, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. Journal of Clinical Investigation. 1997 May 1;99(9):2192-2202.
Tilton, Ronald ; Kawamura, Takahiko ; Chang, Katherine C. ; Ido, Yasuo ; Bjercke, Robert J. ; Stephan, Clifford C. ; Brock, Tommy A. ; Williamson, Joseph R. / Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. In: Journal of Clinical Investigation. 1997 ; Vol. 99, No. 9. pp. 2192-2202.
@article{efd23665d3f24e66a94c415b9bc83ea1,
title = "Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor",
abstract = "The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Skin chambers were mounted on the backs of Sprague-Dawley rats and 1 wk later, granulation tissue in the chamber was exposed twice daily for 7 d to 5 mM glucose, 30 mM glucose, or 1 mM sorbitol in the presence and absence of neutralizing VEGF antibodies. Albumin permeation and blood flow were increased two- to three- fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Blood flow and albumin permeation were increased ~ 2.5-fold 1 h after topical application of recombinant human VEGF and these effects were prevented by nitric oxide synthase (NOS) inhibitors (aminoguanidine and N(G)-monomethyl L-arginine). Topical application of a superoxide generating system increased albumin permeation and blood flow and these changes were markedly attenuated by VEGF antibody and NOS inhibitors. Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore. A23187, mimicked effects of glucose, sorbitol and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by 'hypoxia-like' cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway.",
keywords = "albumin permeation, blood flow, nitric oxide, polyol pathway, vascular endothelial growth factor",
author = "Ronald Tilton and Takahiko Kawamura and Chang, {Katherine C.} and Yasuo Ido and Bjercke, {Robert J.} and Stephan, {Clifford C.} and Brock, {Tommy A.} and Williamson, {Joseph R.}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "99",
pages = "2192--2202",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor

AU - Tilton, Ronald

AU - Kawamura, Takahiko

AU - Chang, Katherine C.

AU - Ido, Yasuo

AU - Bjercke, Robert J.

AU - Stephan, Clifford C.

AU - Brock, Tommy A.

AU - Williamson, Joseph R.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Skin chambers were mounted on the backs of Sprague-Dawley rats and 1 wk later, granulation tissue in the chamber was exposed twice daily for 7 d to 5 mM glucose, 30 mM glucose, or 1 mM sorbitol in the presence and absence of neutralizing VEGF antibodies. Albumin permeation and blood flow were increased two- to three- fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Blood flow and albumin permeation were increased ~ 2.5-fold 1 h after topical application of recombinant human VEGF and these effects were prevented by nitric oxide synthase (NOS) inhibitors (aminoguanidine and N(G)-monomethyl L-arginine). Topical application of a superoxide generating system increased albumin permeation and blood flow and these changes were markedly attenuated by VEGF antibody and NOS inhibitors. Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore. A23187, mimicked effects of glucose, sorbitol and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by 'hypoxia-like' cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway.

AB - The purpose of these experiments was to investigate a potential role for vascular endothelial growth factor (VEGF) in mediating vascular dysfunction induced by increased glucose flux via the sorbitol pathway. Skin chambers were mounted on the backs of Sprague-Dawley rats and 1 wk later, granulation tissue in the chamber was exposed twice daily for 7 d to 5 mM glucose, 30 mM glucose, or 1 mM sorbitol in the presence and absence of neutralizing VEGF antibodies. Albumin permeation and blood flow were increased two- to three- fold by 30 mM glucose and 1 mM sorbitol; these increases were prevented by coadministration of neutralizing VEGF antibodies. Blood flow and albumin permeation were increased ~ 2.5-fold 1 h after topical application of recombinant human VEGF and these effects were prevented by nitric oxide synthase (NOS) inhibitors (aminoguanidine and N(G)-monomethyl L-arginine). Topical application of a superoxide generating system increased albumin permeation and blood flow and these changes were markedly attenuated by VEGF antibody and NOS inhibitors. Application of sodium nitroprusside for 7 d or the single application of a calcium ionophore. A23187, mimicked effects of glucose, sorbitol and VEGF on vascular dysfunction and the ionophore effect was prevented by coadministration of aminoguanidine. These observations suggest a potentially important role for VEGF in mediating vascular dysfunction induced by 'hypoxia-like' cytosolic metabolic imbalances (reductive stress, increased superoxide, and nitric oxide production) linked to increased flux of glucose via the sorbitol pathway.

KW - albumin permeation

KW - blood flow

KW - nitric oxide

KW - polyol pathway

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0031000258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031000258&partnerID=8YFLogxK

M3 - Article

C2 - 9151791

AN - SCOPUS:0031000258

VL - 99

SP - 2192

EP - 2202

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -